2017
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC
Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T. Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2017, 23: 1887-1890. PMID: 29048297, PMCID: PMC5652442, DOI: 10.3201/eid2311.170077.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisHost Mycobacterium tuberculosis diversityMultidrug-resistant TBInfectious Diseases journal - CDCPulmonary TB patientsPulmonary tuberculosis infectionTB patientsTuberculosis infectionPolyclonal infectionsSimple infectionMultidrug resistanceInfectionPatientsTuberculosisPrevalenceDiagnosis
2015
Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens
Chang HH, Cohen T, Grad YH, Hanage WP, O'Brien TF, Lipsitch M. Origin and Proliferation of Multiple-Drug Resistance in Bacterial Pathogens. Microbiology And Molecular Biology Reviews 2015, 79: 101-116. PMID: 25652543, PMCID: PMC4402963, DOI: 10.1128/mmbr.00039-14.Peer-Reviewed Original ResearchConceptsMDR infectionsPublic health threatMultiple drug resistanceHigh prevalenceMore effective interventionsDifferent underlying mechanismsMultidrug resistanceEffective interventionsHealth threatUnderlying mechanismInfectionBacterial pathogensMDRCommon mechanismDifferent pathogensProliferationPathogensPrevalenceHypothetical mechanism
2014
High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova.
Jenkins HE, Crudu V, Soltan V, Ciobanu A, Domente L, Cohen T. High risk and rapid appearance of multidrug resistance during tuberculosis treatment in Moldova. European Respiratory Journal 2014, 43: 1132-41. PMID: 24558181, PMCID: PMC4005038, DOI: 10.1183/09031936.00203613.Peer-Reviewed Original ResearchConceptsMultidrug-resistant tuberculosisMDR-TB diagnosisMDR-TB casesTB treatmentFirst-line TB drugsAmbulatory TB treatmentMDR-TB riskDrug susceptibility testingNosocomial transmissionInitial diagnosisPercentage of individualsTB drugsTuberculosis treatmentEarly treatmentHigh riskSputum specimensSurveillance databasePrevious incarcerationDrug resistanceMultidrug resistanceDiagnosisTreatmentBaseline resistanceRapid appearanceRisk
2012
Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru - Volume 18, Number 5—May 2012 - Emerging Infectious Diseases journal - CDC
Lin HH, Shin SS, Contreras C, Asencios L, Paciorek CJ, Cohen T. Use of Spatial Information to Predict Multidrug Resistance in Tuberculosis Patients, Peru - Volume 18, Number 5—May 2012 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2012, 18: 811-813. PMID: 22516236, PMCID: PMC3358052, DOI: 10.3201/eid1805.111467.Peer-Reviewed Original ResearchMultidrug Resistance Among New Tuberculosis Cases
Hedt BL, van Leth F, Zignol M, Cobelens F, van Gemert W, Nhung NV, Lyepshina S, Egwaga S, Cohen T. Multidrug Resistance Among New Tuberculosis Cases. Epidemiology 2012, 23: 293-300. PMID: 22249242, PMCID: PMC3276714, DOI: 10.1097/ede.0b013e3182459455.Peer-Reviewed Original Research
2011
Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins HE, Zignol M, Cohen T. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009. PLOS ONE 2011, 6: e22927. PMID: 21829557, PMCID: PMC3146514, DOI: 10.1371/journal.pone.0022927.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIncident TB casesTB casesHIV prevalence countriesHigh HIV prevalence countriesPrevalence countriesHigh HIV prevalence areasRetreatment TB casesHIV prevalence areasIsoniazid-resistant tuberculosisControl of tuberculosisEffect of INHObserved time trendsWorld Health OrganizationPreventive therapyResistant tuberculosisIncident casesTreatment successPrevalence areasIsoniazid resistanceMultidrug resistanceHealth OrganizationTuberculosisINHNational dataSpontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy
Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous Emergence of Multiple Drug Resistance in Tuberculosis before and during Therapy. PLOS ONE 2011, 6: e18327. PMID: 21479171, PMCID: PMC3068161, DOI: 10.1371/journal.pone.0018327.Peer-Reviewed Original ResearchConceptsMultiple drug resistanceDrug resistanceInitial treatment regimensTB control programsAnti-TB drugsDrug-resistant formsEmergence of resistanceFunctional monotherapyTreatment regimensCombination therapyTB strainsTuberculosis treatmentTherapy rangeM. tbTB bacilliMultidrug resistanceM. tuberculosisDifferent antibioticsTherapyTuberculosisInfected hostControl programsResistant formsTBMonotherapy
2004
Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness
Cohen T, Murray M. Modeling epidemics of multidrug-resistant M. tuberculosis of heterogeneous fitness. Nature Medicine 2004, 10: 1117-1121. PMID: 15378056, PMCID: PMC2652755, DOI: 10.1038/nm1110.Peer-Reviewed Original ResearchConceptsDrug-sensitive strainsMDR strainsMultidrug resistanceMultidrug-resistant M. tuberculosisM. tuberculosisMultidrug-resistant tuberculosisTuberculosis control effortsEmergence of resistanceTB controlFuture burdenMDR diseaseMDRTB strainsEpidemiological measuresTuberculosisMDRSmall subpopulationMDRTBControl programsBurdenSingle locus mutationsSequential acquisitionDisease